FISHAWACK
1.8.2019 15:02:09 CEST | Business Wire | Press release
2e Creative , an internationally recognised healthcare marketing strategy firm focused on launching pharmaceutical and medical device products, has joined the Fishawack Group , after receiving investment from the global healthcare communications group. The 2e deal strengthens Fishawack as one of the largest independent healthcare communications organisations worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190801005540/en/
“2e has been on an exhilarating growth trajectory for the past several years,” 2e CEO Ross Toohey said. “We chose Fishawack over a host of other potential investors because their global footprint, expansive capabilities, and entrepreneurial culture represented the greatest advantage for our employees and clients. This is truly the next evolutionary leap for 2e and the brands we serve.”
Fishawack is a global healthcare communications group with offices in London, Oxford, Brighton and Manchester, UK, as well as Philadelphia, New York, and San Diego, USA; 2e adds to the group’s US footprint. The firm’s core strengths in medical communications, strategic consulting, and creative, fits nicely with 2e’s expertise in strategy, creative, digital marketing, sales training, and internal communications. With this breadth of capabilities, Fishawack and 2e can now support clients throughout the entire product development, launch, and growth lifecycle. With the 2e partnership, the Fishawack Group now boasts over 750 employees worldwide, making it among the largest independent healthcare agencies globally.
“Fishawack is one of the new generation of leaders in healthcare communications. We’re challenging the major agency networks by fostering a uniquely collaborative culture across our agency collective,” Fishawack CEO Oliver Dennis said. “We offer the capabilities, scale, and geographical coverage to offer healthcare brands a fresh, new type of partnership value. We’re excited about 2e’s portfolio, capabilities, and brilliant people. Ross has built a great entrepreneurial culture, and we can’t wait to work with the 2e team.”
This partnership is particularly notable for 2e because it comes on the heels of the agency’s appointment to the MM&M Top 100 Healthcare Agencies worldwide, as well as 2e’s three consecutive victories (2015, 2016, 2017) as MM&M “Healthcare Agency of the Year.” Between 2e and sister agencies Dudnyk , Carling Communications , Blue Latitude Health , and Healthcircle , the Fishawack Group is among the most award winning in the field of healthcare marketing.
“We’re very deliberate about the agencies we invest in,” Fishawack Group President Gail Flockhart said. “Clients demand seamlessly blended capabilities, so it’s important that we build collaborative allegiances across the Fishawack Group. It’s best for our clients and our people. 2e brings executive training and organisational optimisation capabilities to the group.”
Advisors to Fishawack included KPMG, Addleshaw Goddard LLP, and financial backers LDC and LGT Capital Partners. 2e’s advisors included Results International, Stoll Keenon Ogden PLLC, and Clifton Larson Allen.
About 2e Creative
Founded in 1999, 2e Creative is a launch and growth agency featuring Fortune 50 clients across pharma, medical device, and research biotech. The agency’s core competencies include branding, marketing strategy, digital marketing, sales training, and meeting/event production. 2e has over 150 employees and operations in Missouri, Indiana, Texas, and California.
About the Fishawack Group
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in the UK (Manchester, Oxford, London, and Brighton), the USA (Philadelphia, PA, New York, NY, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).
Fishawack comprises two international divisions, Fishawack Medical Communications , developing and delivering services in the fields of medical communications, scientific engagement, publications, market access, strategic consultancy, and thought leader consultancy, and Fishawack Creative , offering strategic planning, creative development, advertising and promotion, and tactical execution.
We have built our reputation on excellence, creativity, and transparency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190801005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
